

## HR 7667

### Food and Drug Amendments of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 6, 2022

**Current Status:** Received in the Senate.

**Latest Action:** Received in the Senate. (Jun 9, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7667>

## Sponsor

**Name:** Rep. Eshoo, Anna G. [D-CA-18]

**Party:** Democratic • **State:** CA • **Chamber:** House

## Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		May 6, 2022
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		May 6, 2022
Rep. Pallone, Frank, Jr. [D-NJ-6]	D · NJ		May 6, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	May 11, 2022

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 HR 9297	Related bill	<b>Nov 16, 2022:</b> Referred to the Subcommittee on Health.
117 S 4535	Related bill	<b>Jul 14, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4351	Related bill	<b>Jun 6, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4333	Related bill	<b>May 26, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4338	Related bill	<b>May 26, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4302	Related bill	<b>May 25, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
117 S 4152	Related bill	<b>May 5, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 7649	Related bill	<b>May 3, 2022:</b> Referred to the House Committee on Energy and Commerce.
117 HR 7658	Related bill	<b>May 3, 2022:</b> Referred to the House Committee on Energy and Commerce.
117 S 3983	Related bill	<b>Mar 31, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 7084	Related bill	<b>Mar 16, 2022:</b> Referred to the Subcommittee on Health.
117 HR 7006	Related bill	<b>Mar 10, 2022:</b> Referred to the Subcommittee on Health.
117 HR 7032	Related bill	<b>Mar 10, 2022:</b> Referred to the Subcommittee on Health.
117 HR 7035	Related bill	<b>Mar 10, 2022:</b> Referred to the Subcommittee on Health.
117 HR 6980	Related bill	<b>Mar 9, 2022:</b> Referred to the Subcommittee on Health.
117 HR 6988	Related bill	<b>Mar 9, 2022:</b> Referred to the Subcommittee on Health.
117 HR 6888	Related bill	<b>Mar 2, 2022:</b> Referred to the Subcommittee on Health.
117 S 3478	Related bill	<b>Jan 11, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 2952	Related bill	<b>Oct 7, 2021:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 2565	Related bill	<b>Apr 16, 2021:</b> Referred to the Subcommittee on Health.

## Food and Drug Amendments of 2022

This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.

Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.

The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.

In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.

## Actions Timeline

---

- **Jun 9, 2022:** Received in the Senate.
- **Jun 8, 2022:** Considered as unfinished business. (consideration: CR H5402-5403)
- **Jun 8, 2022:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).
- **Jun 8, 2022:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254). (text: 06/07/2022 CR H5298-5319)
- **Jun 8, 2022:** Motion to reconsider laid on the table Agreed to without objection.
- **Jun 7, 2022:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.
- **Jun 7, 2022:** Placed on the Union Calendar, Calendar No. 262.
- **Jun 7, 2022:** Mr. Pallone moved to suspend the rules and pass the bill, as amended.
- **Jun 7, 2022:** Considered under suspension of the rules. (consideration: CR H5298-5321)
- **Jun 7, 2022:** DEBATE - The House proceeded with forty minutes of debate on H.R. 7667.
- **Jun 7, 2022:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **May 18, 2022:** Committee Consideration and Mark-up Session Held.
- **May 18, 2022:** Ordered to be Reported (Amended) by the Yeas and Nays: 55 - 0.
- **May 11, 2022:** Subcommittee Consideration and Mark-up Session Held.
- **May 11, 2022:** Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .
- **May 9, 2022:** Referred to the Subcommittee on Health.
- **May 6, 2022:** Introduced in House
- **May 6, 2022:** Referred to the House Committee on Energy and Commerce.